17 September 2025 - PHARMAC is seeking feedback on a proposal to fund a new brand of methylphenidate to help address ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder.

If approved, the proposal would see Methylphenidate Sandoz XR funded from 1 December 2025. This is a generic equivalent to the Concerta brand and would be available in the same strengths.

Read PHARMAC press release